ABSTRACT
INTRODUCTION
Influenza viruses are responsible for many respiratory infections affecting all age groups, particularly the elderly population [1, 2] . Annual epidemics of seasonal influenza viruses are estimated to result in approximately three to five million cases of severe illness and about 250,000 to 500,000 deaths worldwide (WHO, 2014) . In addition, influenza pandemics, that occur every few decades, pose a major global threat.
Influenza virus genome contains 8 single-stranded RNA molecules, which encodes at least 13 proteins, among them Neuraminidase (NA) and Hemagglutinin (HA), which are expressed on the surface of infected cells [3] [4] [5] . To avoid immune recognition, both the HA and the NA proteins are subjected to extensive antigenic changes, complicating the design of a universal vaccine aiming to target all influenza strains [6] . Thus, the primary preventive strategy currently available against influenza virus infection is a vaccine that is designed and administered each year [7] . The vaccine is composed of three or four influenza virus strains prevailing in the influenza season of the opposite hemisphere.
The most recent influenza pandemic occurred in 2009. Although the mortality rate was relatively low, it affected many people around the world [8] . The pandemic began in La Gloria, Mexico in February 2009 [9] . Since that time, the A(H1N1)pdm09 virus spread rapidly across the globe and early assessments of transmissibility and severity were made [9] . In 2010, the WHO announced that A(H1N1)pdm09 virus is expected to continue circulating as a seasonal virus [10] . Indeed, infections with the virus were noted in subsequent years, accounting for 24.5% of the 2010-2014 infections in North China, 16% of which were in 2013-2014 [11] . In 2012-2013, 28.5% of the influenza-infected individuals in France, Italy, Spain and
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Lithuania together, were infected with influenza A(H1N1) pdm09 [12] . In Austria, 18.3% of the influenza-infected individuals were A(H1N1)pdm09-positive in winter 2014-2015 [13] . During the post-pandemic period in Israel, 10% of the patients hospitalized in 2010-2011 winter season and 5% of those hospitalized in the 2011-2012 winter season, were infected with the A(H1N1)pdm09 virus [6] . These numbers rose in winter 2012-2013, when 20% of the hospitalized patients were infected with the A(H1N1) pdm09 influenza virus, 64.8% of whom were pregnant women [6] . A recent Eurosurveillance report estimated that the northern hemisphere vaccine still offers protection against circulating A(H1N1)pdm09 viruses, because only limited drift has been observed [14] .
Here, we report of a significant A(H1N1)pdm09 Influenza virus infection rate in the last winter season (2015) (2016) in Israel, analyze the virus properties and demonstrate that it differs from the strain included in the vaccine. 
Genetic variations of seasonal A(H1N1)pdm09 viruses
Several A(H1N1)pdm09 viruses were randomly selected from 2015-2016 winter period samples and from samples collected during previous winter seasons, to enable a whole HA gene sequencing (1701 bp, 566 amino acid) and construction of a phylogenetic tree. (Table 1 ). All 6B clade viruses in our analysis contained the amino acid variations that define this clade: D97N, K163Q, S185T, S203T, A256T and K283E (Table 1) [15] [16] [17] . Additional mutations included S84N, S162N and I216T in the 6B.1 clade and V152T, V173I, E491G, D501E in the 6B.2 clade [18] . The last 7 mutations are located on the Hemagglutinin surface ( Figure 5 ). There are four major antigenic sites on the Hemagglutinin protein named -Sa, Sb, Ca, and Cb [19, 20] . Mutations K163Q, S185T, S203T (clade 6B) are respectively located on Sa, Sb and Ca1 antigenic sites. In addition, we found that S162N (clade 6B.1) located in Sa site [21] and V173I (clade 6B.2) in Ca1 site [15] .
Immunity to old and new A(H1N1)pdm09 antigens
Analysis of the symptoms reported by patients infected with A(H1N1)pdm09 virus in 2009 and 2012 versus 2015th circulating 6B clade strains, yielded no significant differences between the patient groups ( Figure  6 ). In addition, to evaluate the potential of serum antibodies collected from individuals to cross-react with the influenza A(H1N1)pdm09 circulating strains, sera from 240 individuals obtained in 2014-2015, prior to the appearance of the current strains. Sera samples were applied in HI assays against the vaccine strain A/California/07/2009 antigen and against two circulating influenza A(H1N1)pdm09 antigens from clade 6B.1 and 6B.2. As seen in Figure 7 , the vaccine strain was better recognized (Figure 7A ), and yielded a higher geometric mean of antibodies titer (GMT Figure 7B) , as compared with the circulating Israel strains.
DISCUSSION
The recent years gave us the opportunity to study the evolution and spread of the pandemic A(H1N1) pdm09 Influenza virus, since the time it first appeared in 2009 until today. At the post-pandemic period, until 2015, HA genes have evolved and eight genetic groups have been designated [6] . Since September 2015, most A(H1N1)pdm09 viruses fell into genetic group 6B and in two emerging subgroups, 6B.1 and 6B.2 [18] . Despite the emergence of new genetic subgroups, a report for the WHO suggested in February 2016 that these 6B clade viruses are antigenically similar to the vaccine virus A/ California/7/2009 [18] .
During the 2015-2016 influenza season at total of 1548 outpatient samples were negative for influenza, of which 194 (12.5%) of them were vaccinated against influenza. To test the vaccination efficiency we compared the odds ratio of vaccinated and non-vaccinated individuals among individuals who were positive and negative for influenza. The odds ratio was 1.18, indicating no difference between the vaccinated and the none- P  TCT  S  TCT  S  84  AGT  S  AAT  N  AGT  S  97  GAT  D  AAT  N  AAT  N  152  GTT  V  GTT  V  ACT  T  162  AGC  S  AAC  N  AGC  S  163  AAA  K  CAA  Q  CAA  Q  173  GTC  V  GTC  V  ATC  I  185  AGT  S  ACT  T  ACT  T  187 GAG [15, [19] [20] [21] , and therefore might result in ineffective immunogenic recognition. Laboratories in the United States and United Kingdom have recently reported maintained effectiveness of the influenza vaccine bearing the A/California/7/2009 strain [22, 23] . However, in contrast to these reports, which used post-infected ferret's sera in their HI assays, we directly compared the HI potential of A/California/7/2009 versus Israeli 6B viruses isolated from patient samples, to identify cross-protecting antibodies in the Israeli population. This analysis significantly demonstrate that the anti-influenza antibodies recognize the circulating Israeli 6B strains 4-fold less efficiently as compared to the vaccinating strain. In line with these findings, the WHO report including recommendations for the northern hemisphere 2015-2016 vaccine composition, states that the GMTs in HI against representative 6B clade viruses were significantly reduced compared to HI titers to the vaccine virus, particularly in pediatric serum panels [18] .
In the past seven years, the A/California/7/2009 strain has been included in the influenza vaccine [24] . However, we show here that the circulating A(H1N1) pdm09 viruses substantially differ from the vaccinating strains and are not adequately recognized by the vaccine strains. In view of these results, we suggest that current circulating strains should be included in the vaccine. 
MATERIALS AND METHODS

Patients and samples
Detection of A(H1N1)pdm09 virus
Viral genomic RNA was extracted from patient samples using the NucliSENS easyMAG (BioMerieux, France). Influenza A, influenza B and A(H1N1)pdm09 strains were identified using a panel of real-time reverse transcription PCR (rRT-PCR), as previously described [25, 26] .
Sample preparation for sequencing
For the phylogenetic analysis, influenza Hemagglutinin gene-specific primers (WHO Swine genome set [27] were amplified using the OneStep RT-PCR Kit (QIAGEN). ExoProStar (Illustrsa) was activated on the cDNA to clean unincorporated primers and dNTPs. The Big Dye ® Terminator v1.1 cycle kit (ABI Prism ® ) was used for sample sequencing, as per the manufacturer's instructions. The BigDye ® Xterminator Purification Kit (ABI) was then used to clean the cDNA. Samples were processed and sequenced in a Genetic Analyzer 3500 (ABI\HITACHI) machine.
Phylogenetic analysis
For the phylogenetic analysis, Influenza Hemagglutinin gene-specific primers were used [6, 27] . The Sequencher ® 5.0 program (Gencodes Corporation, Ann Arbor, MI) was used to compare the nucleotide sequences of the collected samples to HA genes of various Influenza A clades.
The evolutionary relationships and the most recent common ancestor (MRCA) for the influenza A(H1N1)pdm09 virus Hemagglutinin sequences, were calculated using a Bayesian Markov chain Monte Carlo (MCMC) method, applied using a relaxed molecular clock, as implemented in the BEAST program (version 1.7.5). Trees were visualized and edited with the Figure Tree program (version 1.4. 2) included in the BEAST software package [28] .
Hemagglutination inhibition (HI) analysis
All sera were treated (16 h) with receptor destroying enzyme (RDE) (Sigma C8772), diluted 1:4, prior to heat inactivation (30 min, 56°C). Absorption with erythrocytes was then conducted to remove non-specific binding, in accordance with a WHO-recommended protocol [29] . Two-fold serial dilutions (1:40-1:5120) of sera in 25 μl PBS were prepared in V-shaped well plates, and an equal volume of four HA units was added. The mixture was then incubated at room temperature for 1 h. Fifty microliters of 0.5% chicken erythrocytes suspended in PBS, were added to the wells, and mixed by shaking the plates on a mechanical vibrator. Agglutination patterns were read after 30 min and the HI titer was defined as the reciprocal of the last dilution of serum that fully inhibited Hemagglutination. The cut-off value for a positive result was set at 1:40. The influenza A(H1N1)pdm09 (A/ California/07/2009 NYMC X-179A) antigen was supplied by the WHO. The Israeli 6B.1 and 6B.2 clades antigens were A/Israel/Q363/2015 and A/Israel/Q504/2015, respectively.
Statistical analysis
The annual percent of positive cases was calculated by dividing the number of positive A(H1N1)pdm09 samples by the total number of positive tests for Influenza Viruses. The Chi-Square test was applied to evaluate the differences in positivity percent between the compared years. To calculate significant differences of HI results, we used Kruskal-Wallis test (One-way ANOVA on ranks), since the titers have non-normal distributions. All analyses were performed using SPSS. A p-value < 0.05 was considered to be statistically significant.
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